Cargando…

Cognitive and Affective Changes in Mild to Moderate Alzheimer’s Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A 6-Month Observational Study

Patients with Alzheimer’s disease after an initial response to cholinesterase inhibitors may complain a later lack of efficacy. This, in association with incident neuropsychiatric symptoms, may worsen patient quality of life. Thus, the switch to another cholinesterase inhibitor could represent a val...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spalletta, Gianfranco, Caltagirone, Carlo, Padovani, Alessandro, Sorbi, Sandro, Attar, Mahmood, Colombo, Delia, Cravello, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929703/ https://www.ncbi.nlm.nih.gov/pubmed/24586603 http://dx.doi.org/10.1371/journal.pone.0089216

Ejemplares similares

Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study
por: Colombo, Delia, et al.
Publicado: (2018)

Predictors of progression of cognitive decline in Alzheimer’s disease: the role of vascular and sociodemographic factors
por: Musicco, Massimo, et al.
Publicado: (2009)

Good rate of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease after three months of treatment: An open-label study
por: de Miranda, Luis Felipe José Ravic, et al.
Publicado: (2013)

The comparative efficacy and safety of cholinesterase inhibitors in patients with mild‐to‐moderate Alzheimer's disease: a Bayesian network meta‐analysis
por: Kobayashi, Hisanori, et al.
Publicado: (2015)

Depressive symptoms in Parkinson’s disease and in non-neurological medical illnesses
por: Assogna, Francesca, et al.
Publicado: (2013)

Psychiatric profile of motor subtypes of de novo drug‐naïve Parkinson's disease patients
por: Assogna, Francesca, et al.
Publicado: (2018)

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy
por: Wattmo, Carina, et al.
Publicado: (2016)

Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism
por: Assogna, Francesca, et al.
Publicado: (2019)

Atrophy of presubiculum and subiculum is the earliest hippocampal anatomical marker of Alzheimer's disease
por: Carlesimo, Giovanni A., et al.
Publicado: (2015)

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

Identification of Genetic Networks Reveals Complex Associations and Risk Trajectory Linking Mild Cognitive Impairment to Alzheimer’s Disease
por: Strafella, Claudia, et al.
Publicado: (2022)

Prescribing cholinesterase inhibitors in mild cognitive impairment—Observations from the Alzheimer's Disease Neuroimaging Initiative
por: Stage, Eddie, et al.
Publicado: (2021)

Influence of APOE and RNF219 on Behavioral and Cognitive Features of Female Patients Affected by Mild Cognitive Impairment or Alzheimer’s Disease
por: Mosca, Alessandra, et al.
Publicado: (2018)

Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan
por: Ueda, Kengo, et al.
Publicado: (2019)

Myeloid dendritic cells are decreased in peripheral blood of Alzheimer’s disease patients in association with disease progression and severity of depressive symptoms
por: Ciaramella, Antonio, et al.
Publicado: (2016)

Myeloid Dendritic Cells are Potential Players in Human Neurodegenerative Diseases
por: Bossù, Paola, et al.
Publicado: (2015)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Anti-inflammatory Effects of Homotaurine in Patients With Amnestic Mild Cognitive Impairment
por: Bossù, Paola, et al.
Publicado: (2018)

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
por: Han, Hyun Jeong, et al.
Publicado: (2011)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

High serum levels of transforming growth factor β1 are associated with increased cortical thickness in cingulate and right frontal areas in healthy subjects
por: Piras, Fabrizio, et al.
Publicado: (2012)

Brain microstructural changes and cognitive correlates in patients with pure obsessive compulsive disorder
por: Spalletta, Gianfranco, et al.
Publicado: (2014)

GABA System in Schizophrenia and Mood Disorders: A Mini Review on Third-Generation Imaging Studies
por: Chiapponi, Chiara, et al.
Publicado: (2016)

Effectiveness of Nootropics in Combination with Cholinesterase Inhibitors on Cognitive Function in Mild-to-Moderate Dementia: A Study Using Real-World Data
por: Kang, Minjae, et al.
Publicado: (2022)

Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson’s Disease
por: Assogna, Francesca, et al.
Publicado: (2021)

Characteristics of falls in mild and moderate Alzheimer’s disease
por: Kato-Narita, Eliane Mayumi, et al.
Publicado: (2009)

Are Guidelines Needed for the Diagnosis and Management of Incipient Alzheimer's Disease and Mild Cognitive Impairment?
por: Palmer, Katie, et al.
Publicado: (2010)

Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients
por: Bossù, Paola, et al.
Publicado: (2011)

Compliance and Caregiver Satisfaction in Alzheimer's Disease: Results from the AXEPT Study
por: Bernabei, Roberto, et al.
Publicado: (2012)

Alzheimer's disease and Type 2 diabetes mellitus: the cholinesterase connection?
por: Allam, Appa Rao, et al.
Publicado: (2006)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

Cortical Grey Matter and Subcortical White Matter Brain Microstructural Changes in Schizophrenia Are Localised and Age Independent: A Case-Control Diffusion Tensor Imaging Study
por: Chiapponi, Chiara, et al.
Publicado: (2013)

Time Dysperception Perspective for Acquired Brain Injury
por: Piras, Federica, et al.
Publicado: (2014)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Neuropsychological Rehabilitation in Mild and Moderate Alzheimer’s Disease Patients
por: Ávila, Renata, et al.
Publicado: (2007)

The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease
por: Hartry, Ann, et al.
Publicado: (2018)

Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials
por: Raschetti, Roberto, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_lhkt5j8d681r9vpi83imdibrha